ArticleFrontiers in oncology2026
A deep learning model based on multiphase DCE-MRI for preoperative prediction of Ki-67 expression in breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective study was to develop and validate a deep learning model based on multi-phase Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) for non-invasive and accurate prediction of Ki-67 expression, a key proliferation biomarker critical for treatment decision-making and prognostic evaluation in breast cancer. Methods: 404 breast cancer patients who underwent preoperative DCE-MRI within 1 week of surgery were enrolled and randomly split into training (n = 282) and test (n = 122) sets in a 7:3 ratio. Multi-phase DCE-MRI sequences at 3.0T: pre-contrast phase, early phase (64 seconds), peak phase (128 seconds), and late phase (320 seconds) after contrast agent administration. DenseNet-121 was used to build four single-phase deep learning models (SP_DL1-SP_DL4). Their output probabilities (DL signatures) were combined using gradient boosting decision trees (GBDT) to create a multi-phase model (MP_GBDT). Clinical predictors were integrated with DL signatures to build a fused model (CMP_GBDT). Model interpretability was assessed using Grad-CAM and SHAP. Independent samples t-test or Mann-Whitney Results: In the test set, single-phase DL models achieved AUCs of 0.712 (SP_DL1), 0.671 (SP_DL2), 0.761 (SP_DL3), and 0.664 (SP_DL4). The multi-phase DL model (MP_GBDT) achieved an AUC of 0.810, outperforming all single-phase models. The fused model (CMP_GBDT) reached a comparable AUC of 0.814, demonstrating no statistically significant improvement over MP_GBDT. SHAP identified SP_DL3 signature as the top contributor in both MP_GBDT and CMP_GBDT models. Conclusions: The MP_GBDT model accurately and non-invasively predicted Ki-67 expression in breast cancer, with SP_DL3 signature being the main contributor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.